VACCINE ADVERSE EVENTS REPORTING IN VAERS
VAERS: What Data Tells Us - Jessica Rose, PhD - Slides
Vaccine Safety Evidence - June 26, 2021
Assembled by Steve Kirsch with help from Dr. Robert Malone (inventor of the mRNA vaccine)
June 24, 2021
Background: COVID-19 vaccines have had expedited reviews without sufficient safety data. We wanted to compare risks and benefits.
Method: We calculated the number needed to vaccinate (NNTV) from a large Israeli field study to prevent one death. We accessed the Adverse Drug Reactions (ADR) database of the European Medicines Agency and of the Dutch National Register (lareb.nl) to extract the number of cases reporting severe side effects and the number of cases with fatal side effects.
May 20, 2021
Potential problems with C19 mRNA Vaccine, SARS-CoV-2 Antigens, Immune Responses, Spike
SARS-CoV-2 proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. 11 of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day one after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with production of IgG and IgA.